<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomolecules</journal-id><journal-id journal-id-type="iso-abbrev">Biomolecules</journal-id><journal-id journal-id-type="publisher-id">biomolecules</journal-id><journal-title-group><journal-title>Biomolecules</journal-title></journal-title-group><issn pub-type="epub">2218-273X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32075132</article-id><article-id pub-id-type="pmc">7072143</article-id><article-id pub-id-type="doi">10.3390/biom10020303</article-id><article-id pub-id-type="publisher-id">biomolecules-10-00303</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Loh</surname><given-names>Stewart N.</given-names></name></contrib></contrib-group><aff id="af1-biomolecules-10-00303">Department of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; <email>lohs@upstate.edu</email>; Tel.: +1-315-464-8731</aff><pub-date pub-type="epub"><day>14</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2020</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>303</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the author.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The mutational landscape of p53 in cancer is unusual among tumor suppressors because most of the alterations are of the missense type and localize to a single domain: the ~220 amino acid DNA-binding domain. Nearly all of these mutations produce the common effect of reducing p53&#x02019;s ability to interact with DNA and activate transcription. Despite this seemingly simple phenotype, no mutant p53-targeted drugs are available to treat cancer patients. One of the main reasons for this is that the mutations exert their effects via multiple mechanisms&#x02014;loss of DNA contacts, reduction in zinc-binding affinity, and lowering of thermodynamic stability&#x02014;each of which involves a distinct type of physical impairment. This review discusses how this knowledge is informing current efforts to develop small molecules that repair these defects and restore function to mutant p53. Categorizing the spectrum of p53 mutations into discrete classes based on their inactivation mechanisms is the initial step toward personalized cancer therapy based on p53 allele status.</p></abstract><kwd-group><kwd>folding</kwd><kwd>stability</kwd><kwd>structure</kwd><kwd>zinc binding</kwd><kwd>DNA binding</kwd><kwd>metallochaperone</kwd><kwd>aggregation</kwd><kwd>tumor suppressor</kwd><kwd>cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomolecules-10-00303"><title>1. Introduction</title><p>Mutation of the gene encoding for p53&#x02014;a transcription factor and one of the cell&#x02019;s master tumor suppressors&#x02014;is the most recurrent genetic alteration in human cancer [<xref rid="B1-biomolecules-10-00303" ref-type="bibr">1</xref>,<xref rid="B2-biomolecules-10-00303" ref-type="bibr">2</xref>]. Nearly all these mutations cause p53 to lose its ability to properly recognize DNA and/or activate expression of its large complement of other tumor-suppressing genes [<xref rid="B3-biomolecules-10-00303" ref-type="bibr">3</xref>,<xref rid="B4-biomolecules-10-00303" ref-type="bibr">4</xref>]. In addition, a subset of p53 mutations appears to also act by introducing an oncogenic gain-of-function (GOF) by as-yet undefined pathways [<xref rid="B5-biomolecules-10-00303" ref-type="bibr">5</xref>]. Consequently, a longstanding priority in cancer therapy is to develop drugs that restore transcriptional activity to mutant p53s, as well as inhibit their cancer-driving GOF properties. Because p53 is inactivated in many cancers, such drugs would likely have broad clinical impact. Indeed, it has been demonstrated that restoring proper function to mutant p53 is sufficient to kill a variety of tumors in mouse models [<xref rid="B6-biomolecules-10-00303" ref-type="bibr">6</xref>,<xref rid="B7-biomolecules-10-00303" ref-type="bibr">7</xref>,<xref rid="B8-biomolecules-10-00303" ref-type="bibr">8</xref>].</p><p>The mutational landscape of p53 has several singular features that would seem to lend themselves to achieving the above goal. The majority of p53 tumorigenic mutations are of the missense variety (<uri xlink:href="http://p53.iarc.fr">http://p53.iarc.fr</uri>), as opposed to the nonsense, frameshift, and deletion types that predominate in other tumor suppressors such as BRCA1/2 (<uri xlink:href="http://arup.utah.edu/database/BRCA">http://arup.utah.edu/database/BRCA</uri>), retinoblastoma-1 (<uri xlink:href="http://rb1-lovd.d-lohmann.de">http://rb1-lovd.d-lohmann.de</uri>), and PTEN (<uri xlink:href="http://www.lovd.nl/PTEN">http://www.lovd.nl/PTEN</uri>). Efforts to study p53 mutants are greatly aided by the fact that ~90 % of them map to a single domain, the ~220-amino acid DNA-binding domain (DBD), with one-third occurring at one of eight hot-spot codons in DBD [<xref rid="B9-biomolecules-10-00303" ref-type="bibr">9</xref>]. To that end, the solution of the X-ray crystal structure of DBD in 1994 [<xref rid="B10-biomolecules-10-00303" ref-type="bibr">10</xref>] and almost three decades of subsequent biophysical and biochemical analysis have defined some of the primary mechanisms by which the hot-spot mutations cause p53 to lose function (<italic>vide infra</italic>).</p><p>Why, then, are there no mutant p53-targeted drugs available to treat cancer patients? There are at least two root causes. First, there are few examples of drugs that target non-enzymatic, non-receptor proteins. In the case of p53, the drug would need to activate the mutant proteins but not stimulate wild-type (WT) p53, as the latter risks massive cell death due to widespread apoptosis and senescence [<xref rid="B11-biomolecules-10-00303" ref-type="bibr">11</xref>]. This prospect is inherently more difficult than inhibiting protein function, the more common mode of action taken by the conventional drugs mentioned above. The second challenge, and that to which this review is directed, is that mutations act by different mechanisms, and therefore a drug that reactivates one mutant type may have no effect on another. There is a pressing need to classify mutations according to their effects on the structural, biophysical, and biochemical properties of p53, as well as on clinical features such as tumor development, metastasis, and response to therapy [<xref rid="B12-biomolecules-10-00303" ref-type="bibr">12</xref>]. Only by doing so can the promise of treating cancer patients with drugs tailored to their p53 allele status start to become reality.</p><p>Here, we review the mechanisms by which missense mutations inactivate p53, strategies for categorizing mutants, and recent progress towards rescuing mutants by small molecules, interpreted through the lens of those classifications. We limit the focus to studies that target mutant DBD with the intended effect of restoring WT-like conformation and function. GOF remains poorly understood and is somewhat controversial [<xref rid="B13-biomolecules-10-00303" ref-type="bibr">13</xref>], and, in general, a different set of tools is utilized when endeavoring to suppress GOF activities. These and other orthogonal approaches, such as selectively degrading mutant p53, disrupting interactions with p53 binding partners, inhibiting downstream signaling pathways, and exploiting synthetic lethality, have been reviewed recently [<xref rid="B5-biomolecules-10-00303" ref-type="bibr">5</xref>,<xref rid="B14-biomolecules-10-00303" ref-type="bibr">14</xref>,<xref rid="B15-biomolecules-10-00303" ref-type="bibr">15</xref>]. We note, however, that restoring WT function to p53 mutants will serve to eliminate mutant GOF as well2. Three Classes of Tumorigenic p53 Mutations </p><p>p53 consists of three domains: N-terminal transactivation (TAD; residues 1&#x02013;89), central DNA binding (DBD; residues 94&#x02013;312 (<xref ref-type="fig" rid="biomolecules-10-00303-f001">Figure 1</xref>)), and C-terminal oligomerization (OD; residues 95&#x02013;393). Tetramerization and nuclear entry sequences are encoded in the OD. Once p53 has bound to DNA, the TAD is responsible for recruiting general transcription factors and RNA Pol II for gene expression [<xref rid="B16-biomolecules-10-00303" ref-type="bibr">16</xref>]. TAD is also the primary site of MDM2 binding, the E3 ligase that works with MDMX to ubiquitinate p53 (at the OD) and flag it for proteasomal degradation. Compounds that disrupt the p53-MDM2/MDMX axis [<xref rid="B17-biomolecules-10-00303" ref-type="bibr">17</xref>] are the subject of more clinical trials than any other class of p53-related drugs, although their application is mainly for cancers with WT p53 and they bind to MDM2 rather than p53.</p><p>DBD is the largest of the domains and home to ~90 % of known tumorigenic mutations. It is the only domain that does not contain extensive regions of intrinsic disorder, which has facilitated its high-resolution structural determination (<xref ref-type="fig" rid="biomolecules-10-00303-f001">Figure 1</xref>). Fersht and colleagues were the first to categorize DBD mutants based on their structural, biophysical, and biochemical properties [<xref rid="B18-biomolecules-10-00303" ref-type="bibr">18</xref>,<xref rid="B19-biomolecules-10-00303" ref-type="bibr">19</xref>,<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>,<xref rid="B21-biomolecules-10-00303" ref-type="bibr">21</xref>]. The <bold>DNA-contact class</bold> is defined by a reduction in DBD&#x02019;s affinity for DNA (1/<italic>K<sub>d</sub></italic><sup>DNA</sup>) without a reduction in its affinity for its single essential zinc ion (1/<italic>K<sub>d</sub></italic><sup>Zn</sup>) or its free energy of folding (&#x00394;G<sub>fold</sub>) in the absence of zinc. A DNA contact mutation is suggested by its presence in the DNA-binding groove and is confirmed by measuring <italic>K<sub>d</sub></italic><sup>DNA</sup> by electromobility shift or fluorescence assay. Alterations in any residue in direct contact with DNA have thus far been found to increase <italic>K<sub>d</sub></italic><sup>DNA</sup>. Like all transcription factors, p53 employs positively charged side chains to interact with the polyanionic DNA backbone, and mutations of Arg residues (such as R248Q and R273H; <xref ref-type="fig" rid="biomolecules-10-00303-f001">Figure 1</xref>) are a recurrent theme in human cancers (<xref rid="biomolecules-10-00303-t001" ref-type="table">Table 1</xref>). In addition to being common, these mutants are the most pernicious: there is not yet an established paradigm for rationally designing molecules that restore proper DNA-binding affinity.</p><p>The <bold>stability class</bold> of mutants is characterized by the loss of folding free energy without a reduction in DNA- or Zn<sup>2+</sup>-binding affinity under the conditions in which the protein is folded. Destabilization is measured quantitatively by chemical denaturation of the zinc-free protein at low temperature (&#x00394;G<sub>fold</sub>), or qualitatively by apparent melting temperature (T<sub>m</sub>; DBD aggregates at elevated temperatures and thermal denaturation is typically irreversible). Stability mutations are frequently found in the &#x003b2;-sandwich core of DBD, distant from both the DNA- and Zn<sup>2+</sup>-binding sites, with prime examples being Y220C (<xref ref-type="fig" rid="biomolecules-10-00303-f001">Figure 1</xref>; <xref rid="biomolecules-10-00303-t001" ref-type="table">Table 1</xref>) and V143A, a well-known, temperature-sensitive mutant. DBD is only just folded at physiological temperatures (T<sub>m</sub> 42&#x02013;45 &#x000b0;C), and reducing &#x00394;G<sub>fold</sub> by as little as 1 - 2 kcal/mol is sufficient to cause appreciable unfolding, aggregation, and loss of function at physiological temperatures [<xref rid="B19-biomolecules-10-00303" ref-type="bibr">19</xref>,<xref rid="B25-biomolecules-10-00303" ref-type="bibr">25</xref>]. </p><p>The <bold>zinc-binding class</bold> of mutations was originally inferred by their proximity to the metal-binding site [<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>]. The zinc ion is coordinated by C176, H179, C238, and C242; mutations of C176 and H179 are the 7th and 8th most common in the p53 database (<xref rid="biomolecules-10-00303-t001" ref-type="table">Table 1</xref>). The removal of Zn<sup>2+</sup> elicits structural changes, particularly in the loop that contains the DNA contact residue R248, that results in loss of DNA-binding specificity [<xref rid="B22-biomolecules-10-00303" ref-type="bibr">22</xref>]. It also destabilizes DBD, causing it to cycle more rapidly between native and unfolded states [<xref rid="B26-biomolecules-10-00303" ref-type="bibr">26</xref>]. The net result is a progressive loss of function even under native conditions, because a fraction of zinc-free DBD (apoDBD) molecules becomes kinetically trapped in misfolded, aggregation-prone conformations with each unfolding&#x02013;folding cycle [<xref rid="B25-biomolecules-10-00303" ref-type="bibr">25</xref>,<xref rid="B26-biomolecules-10-00303" ref-type="bibr">26</xref>,<xref rid="B27-biomolecules-10-00303" ref-type="bibr">27</xref>]. Although it is true that mutations in the metal-binding pocket will almost certainly weaken zinc affinity, it is possible that other mutations may also increase <italic>K<sub>d</sub></italic><sup>Zn</sup> and be mistakenly assumed to belong to one of the other classes due to their distance from the zinc site. This underscores the need to classify mutants based on functional and biophysical data as well as on structural location, as discussed below.</p></sec><sec id="sec2-biomolecules-10-00303"><title>2. Crosstalk Between Mutational Classes </title><p>The three mutational classes involve distinct types of structural defects. These mutations, however, exert certain shared effects on folding and binding and it may be possible to exploit these commonalities in drug development. For example, the binding of zinc, like that of any ligand, is inextricably linked to protein folding and vice versa. Expressing this relationship as two coupled equilibria (Equation (1) and Equation (2)) helps to illustrate how zinc-binding and stability mutations are related. Zinc-binding mutants weaken metal binding (1/<italic>K<sub>d</sub></italic><sup>Zn</sup> decreases; Equation (2)) without disrupting any interactions that affect the folding of the protein the in absence of metal (<italic>K<sub>fold</sub></italic> remains constant; Equation (1)). By contrast, stability mutants introduce core packing or other defects that shift the population to the unfolded form (<italic>K<sub>fol</sub></italic><sub>d</sub> decreases) but do not affect the ability of the folded protein to bind zinc (<italic>K<sub>d</sub></italic><sup>Zn</sup> remains the same). <italic>K<sub>d</sub></italic><sup>Zn</sup> and <italic>K<sub>fold</sub></italic> can be measured independently [<xref rid="B23-biomolecules-10-00303" ref-type="bibr">23</xref>] and, by doing so, zinc-binding mutants can be identified and their severity quantified, regardless of their location in the structure. Both mutational classes produce the same net effect of decreasing the population of functional DBD (DBD<sub>folded</sub>). The interdependence of Equation (1) and Equation (2) suggests that drugs that elevate intracellular zinc concentration ([Zn<sup>2+</sup>]<sub>free</sub>) may also refold stability mutants, and drugs that stabilize DBD may also rescue zinc-binding mutants, or reactivate p53 that has been demetallated by abnormally low [Zn<sup>2+</sup>]<sub>free</sub>.
<disp-formula id="FD1-biomolecules-10-00303"><label>(1)</label><mml:math id="mm1"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>D</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>&#x021c4;</mml:mo><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>D</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD2-biomolecules-10-00303"><label>(2)</label><mml:math id="mm2"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>D</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>Z</mml:mi><mml:msup><mml:mi>n</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x021c4;</mml:mo><mml:mi>D</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>d</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The mutational categories are not mutually exclusive. Due to the cooperativity of the protein structure, a given alteration often affects more than one property, and this knowledge may help direct potential treatments. For instance, R249 is not in contact with DNA, and its substitution by Ser reduces &#x00394;G<sub>fold</sub> by 1.9 kcal/mol. The structural effects of R249S propagate to the DNA binding site [<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>], however, making it a mixed-stability/DNA-contact mutation that would benefit from eventual combination therapy. </p><p>Mutation-induced aggregation/amyloid formation is a class-crossing pathway by which p53 loses function. p53 aggregation has long plagued in vitro experiments [<xref rid="B19-biomolecules-10-00303" ref-type="bibr">19</xref>,<xref rid="B22-biomolecules-10-00303" ref-type="bibr">22</xref>] but only recently have its underlying mechanisms been characterized and its relevance been extended to human tumor tissue. Generally, a soluble protein aggregates as a result of partial unfolding and subsequent exposure of a cryptic &#x02018;sticky&#x02019; segment. One such amyloidogenic sequence was identified as residues 252&#x02013;258 in DBD, which form a beta strand in the native structure [<xref rid="B28-biomolecules-10-00303" ref-type="bibr">28</xref>,<xref rid="B29-biomolecules-10-00303" ref-type="bibr">29</xref>]. As mentioned, zinc-binding and stability class mutations increase both the equilibrium population of partially unfolded forms and the rate at which they accumulate during the natural unfolding&#x02013;folding cycle. Purified WT DBD forms amyloid fibrils under moderately destabilizing conditions [<xref rid="B30-biomolecules-10-00303" ref-type="bibr">30</xref>] and aggregation is exacerbated by the hot-spot mutations Y220C [<xref rid="B31-biomolecules-10-00303" ref-type="bibr">31</xref>], R175H [<xref rid="B32-biomolecules-10-00303" ref-type="bibr">32</xref>], and R248Q [<xref rid="B33-biomolecules-10-00303" ref-type="bibr">33</xref>]. An ex vivo study of biopsied human tumors found evidence of p53 aggregation (observed as punctate structures accumulating in the nucleus) that correlated with the presence of DBD mutations, including R175H and H179Y (zinc-binding class), Y220C (stability class), and R248L and R273H (DNA-binding class) [<xref rid="B34-biomolecules-10-00303" ref-type="bibr">34</xref>]. Parenthetically, the authors noted that p53 aggregation induced a heat-shock-like stress response and speculated that the resulting dysregulation of protein homeostasis may contribute to GOF phenotypes and the apparent addiction of tumor cells to mutant p53. Even WT p53 was found to form nuclear inclusions under conditions where its transcriptional activity was compromised, suggesting that an elevated intracellular p53 protein load (caused by diminished MDM2 expression,) coupled with its inherent instability, are sufficient to drive aggregation. </p></sec><sec id="sec3-biomolecules-10-00303"><title>3. Rescuing Stability Class Mutants: Cavity Binders </title><p>The so-called cavity binders are designed to selectively interact with the native form of the target protein and not with unfolded or misfolded forms (or with other proteins). Analogous to zinc binding (Equation (2)), drug&#x02013;protein binding energy is used to drive the refolding of an unstable mutant. A drug that binds with a low <italic>K</italic><sub>d</sub> value is doubly important here, not only for the usual reason of minimizing dosage but also because higher affinity confers the ability to refold more severely destabilized mutants at any given drug concentration. The development of cavity binders has been challenged by the general lack of unique crevices or pockets on the surface of DBD, other than the DNA-binding groove itself. One notable exception is the small cavity left by truncation of the Tyr side chain in the Y220C stability class mutant (<xref ref-type="fig" rid="biomolecules-10-00303-f001">Figure 1</xref>). The carbazole derivative PK083 (<xref ref-type="fig" rid="biomolecules-10-00303-f002">Figure 2</xref>) was the first molecule developed to capitalize on this mutant-specific lesion, binding to Y220C p53 with <italic>K<sub>d</sub></italic> ~150 &#x003bc;M, increasing its T<sub>m</sub>, slowing its rates of unfolding and aggregation, and partially restoring its apoptotic activity in cultured cells [<xref rid="B35-biomolecules-10-00303" ref-type="bibr">35</xref>,<xref rid="B36-biomolecules-10-00303" ref-type="bibr">36</xref>]. </p><p>The affinity of Y220C cavity binders has progressively improved in recent years. Halogenating the pharmacophore scaffolds enhances their interaction with Lewis bases (such as the thiolate of C220) via halogen bonding [<xref rid="B37-biomolecules-10-00303" ref-type="bibr">37</xref>]. Trifluorinating the N-ethyl group in the carbazole ring of PK083 lowered its <italic>K<sub>d</sub></italic> by 5-fold [<xref rid="B38-biomolecules-10-00303" ref-type="bibr">38</xref>]. Screening a library of iodinated aromatic compounds identified a new iodinated phenol chemotype that bound Y220C with <italic>K<sub>d</sub></italic> = 184 &#x003bc;M, and chemical modification reduced this value to 9.7 &#x003bc;M (PK5196) [<xref rid="B39-biomolecules-10-00303" ref-type="bibr">39</xref>]. Very recently, optimization of the carbazole and iodophenol cores yielded PK9318/PK9328 [<xref rid="B40-biomolecules-10-00303" ref-type="bibr">40</xref>] and MB710 [<xref rid="B41-biomolecules-10-00303" ref-type="bibr">41</xref>] (<xref ref-type="fig" rid="biomolecules-10-00303-f002">Figure 2</xref>), respectively, which binds Y220C with affinities in the 2&#x02013;4 &#x003bc;M range and increases T<sub>m</sub> by 2&#x02013;4 &#x000b0;C. These compounds achieved &#x0003e;50 % killing of several p53&#x02013;220C cancer cell lines at concentrations of 10&#x02013;30 &#x003bc;M. MB710 was reasonably well-tolerated by WT p53 cell lines, but PK9318 and PK9328 demonstrated significant toxicity toward p53 knockout control cells, illustrating the need to further optimize the affinity and selectivity of binding.</p><p>Despite the steady gains made toward developing Y220C-specific drugs, a major gap remains in the ability to target other stability-class mutants for which no obvious pocket exists in static X-ray crystal structures. Computational simulations are revealing the dynamic and heterogeneous nature of conformational space that proteins naturally explore, especially when they are on the verge of unfolding, as is the case with DBD at 37 &#x000b0;C. These motions expose transient sites that can potentially be drugged. Combined molecular dynamics (MD)/experimental studies of R175H [<xref rid="B42-biomolecules-10-00303" ref-type="bibr">42</xref>] and Y220C [<xref rid="B43-biomolecules-10-00303" ref-type="bibr">43</xref>,<xref rid="B44-biomolecules-10-00303" ref-type="bibr">44</xref>] DBD found evidence for previously hidden subpockets, the latter of which were useful in the aforementioned affinity optimizations. More recently, MD simulations of WT DBD and the stability-class V143A mutant found differences in the turn region between two beta strands (residues 208&#x02013;213) [<xref rid="B45-biomolecules-10-00303" ref-type="bibr">45</xref>]. The turn adopts an &#x02018;open&#x02019; conformation in V143A that the authors hypothesized could be exploited for the rescue of this mutant, as well as other members of the stability class. On the experimental side, phage display-panning of random peptide libraries yielded 7&#x02013;12 amino acid peptides (pCAPs) that appear to preferentially bind to the native state of p53 (WT, R175H, R249S, and V143A variants) and stabilize it against unfolding [<xref rid="B46-biomolecules-10-00303" ref-type="bibr">46</xref>]. One of the peptides was shown to bind WT DBD with <italic>K<sub>d</sub></italic> ~ 21 &#x003bc;M, although the site of interaction has not yet been determined.</p></sec><sec id="sec4-biomolecules-10-00303"><title>4. Rescuing Zinc-Binding Class Mutants: Zinc Metallochaperones </title><p>One can envision two basic mechanisms by which drugs can reinstate proper metal binding status to zinc-binding mutants. The first is binding to a secondary location on p53, changing the conformation of the zinc binding site, and restoring <italic>K<sub>d</sub><sup>Zn</sup></italic> to the wild-type value. The other is raising intracellular [Zn<sup>2+</sup>]<sub>free</sub> to concentrations greater than <italic>K<sub>d</sub><sup>Zn</sup></italic> of the mutant p53. No molecule possessing the former activity has yet been discovered, but several &#x02018;zinc metallochaperones&#x02019; (ZMCs) have been identified that act by means of the latter. In addition to the high-affinity, native Zn<sup>2+</sup>-binding pocket, DBD contains weaker, non-native sites, presumably comprised of its other seven Cys and nine His residues. Zinc misligation to these non-native sites traps DBD in a misfolded state and causes it to aggregate [<xref rid="B26-biomolecules-10-00303" ref-type="bibr">26</xref>]. A ZMC is defined as a molecule that: (i) delivers zinc into the cell (ionophore activity), and then (ii) maintains intracellular Zn<sup>2+</sup><sub>free</sub> at concentrations appropriate for remetallating and refolding mutant DBD (zinc buffering activity) [<xref rid="B47-biomolecules-10-00303" ref-type="bibr">47</xref>]. Zinc buffering is established by adjusting the <italic>K<sub>d</sub><sup>Zn</sup></italic> of the ZMC higher than that of the native site on the given mutant and lower than the collective <italic>K<sub>d</sub><sup>Zn</sup></italic> of the non-native sites, which is assumed to be similar from mutant to mutant. </p><p>Zinc metallochaperone-1 (ZMC1) was the first small molecule shown to reactivate mutant p53 by the above mechanism [<xref rid="B48-biomolecules-10-00303" ref-type="bibr">48</xref>]. One ZMC1 provides a Zn<sup>2+</sup> half-site via the sulfur, &#x003b2;-nitrogen, and pyridinyl nitrogen from the thiosemicarbazone scaffold (<xref ref-type="fig" rid="biomolecules-10-00303-f003">Figure 3</xref>). Upon interaction with zinc, ZMC1 deprotonates and enolizes, creating the active (ZMC1)<sub>2</sub>Zn complex (<xref ref-type="fig" rid="biomolecules-10-00303-f003">Figure 3</xref>), the charge-neutrality of which is thought to be important for its ionophore activity [<xref rid="B49-biomolecules-10-00303" ref-type="bibr">49</xref>]. ZMC1 transiently raises intracellular [Zn<sup>2+</sup><sub>free</sub>] to levels (10&#x02013;20 nM) that are appropriate for refolding R175H p53 and several other members of the zinc-binding class [<xref rid="B49-biomolecules-10-00303" ref-type="bibr">49</xref>]. In concordance, ZMC1 induces R175H-specific killing of tumor cell lines and human tumor xenografts [<xref rid="B50-biomolecules-10-00303" ref-type="bibr">50</xref>,<xref rid="B51-biomolecules-10-00303" ref-type="bibr">51</xref>]. Several closely related molecules (the thiosemicarbazone ZMC2 and the selenosemicarbazone ZMC3) possess similar activities [<xref rid="B52-biomolecules-10-00303" ref-type="bibr">52</xref>]. The semithiocarbazone COTI-2 may exert its antitumor effects at least in part through a ZMC mechanism, although it also induces apoptosis by p53-independent pathways [<xref rid="B53-biomolecules-10-00303" ref-type="bibr">53</xref>,<xref rid="B54-biomolecules-10-00303" ref-type="bibr">54</xref>]</p><p>In addition to ionophore and zinc buffering, a third activity of ZMC1&#x02014;reactive oxygen species (ROS) generation&#x02014;seems to play a role in p53 activation and cell death. ROS stimulates damage response pathways that post-translationally modify p53 to enhance its nuclear entry, recruitment of transcriptional machinery, and resistance to turnover [<xref rid="B55-biomolecules-10-00303" ref-type="bibr">55</xref>]. Zinc ions exist only in a single oxidation state and cannot generate ROS, but it was shown that ZMC1 binds copper ions in the cell and creates ROS by as-yet uncharacterized reactions [<xref rid="B56-biomolecules-10-00303" ref-type="bibr">56</xref>]. In agreement, cellular ROS scavengers such as N-acetyl cysteine do not affect ZMC1&#x02019;s power to refold mutant p53, but inhibit the ability of the newly-reconformed protein to carry out its transcriptional program [<xref rid="B23-biomolecules-10-00303" ref-type="bibr">23</xref>]. A recent study suggested that this property of ZMCs may be exploited to localize their potency to tumor sites. An alternative zinc-binding scaffold (nitrilotriacetic acid) was developed that reduced copper affinity by ~10<sup>6</sup>-fold relative to ZMC1 [<xref rid="B57-biomolecules-10-00303" ref-type="bibr">57</xref>]. The cancer-cell-killing effect of these molecules synergized with chemotherapeutic agents and radiation, which served to supply ROS for p53 post-translational modification. One clearly must be alert to off-target toxicity caused by ZMC-mediated ROS, although these effects are not always undesirable. The aforementioned ZMC1-copper study found that ZMC1 arrested patient-derived glioblastoma cells at picomolar concentrations, due to ROS-induced depletion of deoxyribosyl purines [<xref rid="B56-biomolecules-10-00303" ref-type="bibr">56</xref>].</p><p>Miller et al. took a creative approach by combining ZMC and cavity-binding functionalities in a single molecule [<xref rid="B58-biomolecules-10-00303" ref-type="bibr">58</xref>]. A Zn<sup>2+</sup>-chelating pyridylmethyl moiety was mated to the Y220C-binding iodophenol core to create compound L5 (<xref ref-type="fig" rid="biomolecules-10-00303-f003">Figure 3</xref>). Its zinc-binding properties were consistent with those of ZMC1 and the compound elevated intracellular [Zn<sup>2+</sup>]<sub>free</sub> levels, as expected. Treating a p53-Y220C stomach cancer cell line with L5 increased expression of p53 target genes, suggesting partial restoration of p53 function. L5 was reasonably cytotoxic towards this cancer cell line (IC<sub>50</sub> = 1.7 &#x003bc;M) but also killed a WT p53 cell line at a similar dosage, again stressing the need for greater selectivity toward mutant p53 and reducing off-target effects. It is likely that the poor affinity of the starting scaffold for Y220C (<italic>K<sub>d</sub></italic> ~200 &#x003bc;M [<xref rid="B39-biomolecules-10-00303" ref-type="bibr">39</xref>]) is at least partly to blame.</p></sec><sec id="sec5-biomolecules-10-00303"><title>5. Rescuing DNA Contact Mutants </title><p>DNA-binding mutations can either remove a few protein&#x02013;DNA contact points without altering the overall structure of the DNA-binding groove (e.g., R273H and R248Q) or distort the DNA-binding groove without changing any of the residues that contact DNA in WT DBD (e.g., R249S) [<xref rid="B59-biomolecules-10-00303" ref-type="bibr">59</xref>]. In either case, there is no established strategy for replacing lost protein&#x02013;DNA interactions using exogenous molecules, and this class is considered the most challenging to drug. Nevertheless, intragenic suppressor mutations have been shown to rescue transcriptional functions of R273H and R249S p53 in mammalian cells [<xref rid="B60-biomolecules-10-00303" ref-type="bibr">60</xref>], suggesting that the conformation of the DNA-binding pocket may be somewhat malleable and subject to change by interactions at a distant site [<xref rid="B59-biomolecules-10-00303" ref-type="bibr">59</xref>]. Indeed, an NMR study of DBD found increased dynamic motions in R273H DBD, compared to R248Q and WT, that spanned the DNA-binding surface and the &#x003b2;-sandwich core [<xref rid="B61-biomolecules-10-00303" ref-type="bibr">61</xref>]. The authors concluded that R273H exhibits properties of a both a DNA-contact and conformational mutation, whereas R248Q is a classic DNA-contact mutation.</p><p>Very recently, a tryptophanol-derived oxazoloisoindolinone (SLMP53-1; <xref ref-type="fig" rid="biomolecules-10-00303-f004">Figure 4</xref>) was reported to activate the transcriptional function of the DNA-contact mutant R280K, as well as other hot-spot variants of p53 [<xref rid="B62-biomolecules-10-00303" ref-type="bibr">62</xref>]. Thermal shift assays showed that SLMP53-1 bound directly to R280K DBD with an apparent <italic>K<sub>d</sub></italic> of 10.7 &#x003bc;M. Molecular docking simulations of the p53 tetramer-DNA complex predicted that SLMP53-1 forms a sandwich-like interaction between Met243s of DBD dimers (on the opposite side of the DNA from R280) and several DNA bases, potentially buttressing the DBD&#x02013;DNA interaction and partially compensating for the loss of hydrogen bonds from R280 to a guanine base in the major groove. In cell culture assays, SLMP53-1 rescued other p53 mutants from the DNA-contact class (R248Q, R248W, R273H, R282Q), zinc-binding class (R175H), and stability class (G245S). This result is not inconsistent with the proposed mode of action, because strengthening the DBD&#x02013;DNA interaction may be expected to enhance the transcriptional function of p53 regardless of mutation. In fact, SLMP53-1 also activates WT p53 for cell killing [<xref rid="B63-biomolecules-10-00303" ref-type="bibr">63</xref>], an effect that would ideally need to be mitigated in future iterations of this compound.</p></sec><sec id="sec6-biomolecules-10-00303"><title>6. Rescuing p53 Aggregation </title><p>Aggregation can be considered as a sink that draws p53 mutants into a nonfunctional state that&#x02019;s not only refractory to rescue, but conceivably oncogenic due to GOF. All three p53 mutational classes are associated with aggregation, via their common effect of elevating intracellular p53 concentrations as well as through enhancing populations of aggregation-prone forms (zinc-binding and stability mutants). Molecules that inhibit aggregation therefore have the potential to treat a broad spectrum of p53 mutants [<xref rid="B64-biomolecules-10-00303" ref-type="bibr">64</xref>,<xref rid="B65-biomolecules-10-00303" ref-type="bibr">65</xref>]. A strategy proven effective in inhibiting amyloid fibril formation is to identify the self-adhesive segment of a protein (termed the &#x0201c;steric zipper&#x0201d; [<xref rid="B66-biomolecules-10-00303" ref-type="bibr">66</xref>]) and deploy decoy peptides of similar sequence to mask this segment and block fibril growth. One such steric zipper was found to be residues 252&#x02013;258 of DBD (LTIITLE) [<xref rid="B28-biomolecules-10-00303" ref-type="bibr">28</xref>]. The 17-residue ReACp53 peptide was created by linking the related LTRITLE sequence with a poly-Arg cell-penetrating tag [<xref rid="B67-biomolecules-10-00303" ref-type="bibr">67</xref>]. In primary human cancer cells harboring a variety of p53 mutations, and in organoid tumor cells bearing R248Q and R175H p53, ReACp53 reduced cytosolic p53 aggregates, facilitated p53 entry into the nucleus, and induced apoptosis in a p53 mutant-specific manner. A more recent report found similarly encouraging results in cultured prostate cancer cells and xenografts [<xref rid="B68-biomolecules-10-00303" ref-type="bibr">68</xref>].</p><p>It is unclear why simply preventing p53 aggregation can apparently reactivate mutants such as R248Q and R175H in cells, given the extents to which the DNA- and zinc-binding properties of their respective DBDs are compromised. One possibility is that their inherently poor transcriptional activities can be overwhelmed by their sheer number as a large cellular pool of aggregated p53 converts to native monomers, dimers, and tetramers. Another explanation may be the abrogation of GOF. On the other side of the coin, cavity binders and zinc metallochaperones are expected to inhibit p53 aggregation by reducing the populations of partially unfolded forms that expose adhesive segments. Evidence suggests that PK083 [<xref rid="B31-biomolecules-10-00303" ref-type="bibr">31</xref>] and ZMC1 [<xref rid="B52-biomolecules-10-00303" ref-type="bibr">52</xref>] indeed produce this effect. In addition to these synthetic molecules, natural products including DNA [<xref rid="B69-biomolecules-10-00303" ref-type="bibr">69</xref>,<xref rid="B70-biomolecules-10-00303" ref-type="bibr">70</xref>], RNA [<xref rid="B71-biomolecules-10-00303" ref-type="bibr">71</xref>], polyarginine [<xref rid="B72-biomolecules-10-00303" ref-type="bibr">72</xref>], and the plant phenol resveratrol [<xref rid="B73-biomolecules-10-00303" ref-type="bibr">73</xref>] have been shown to suppress or otherwise modulate p53 aggregation. In any case, it seems likely that the combination of aggregation inhibitors with class-specific reactivators will be an especially fruitful therapeutic strategy.</p></sec><sec id="sec7-biomolecules-10-00303"><title>7. Alkylating Agents </title><p>Some of the first small molecules that were reported to reactivate mutant p53 (e.g., CP-31398 [<xref rid="B74-biomolecules-10-00303" ref-type="bibr">74</xref>] and PRIMA-1/APR-246 [<xref rid="B75-biomolecules-10-00303" ref-type="bibr">75</xref>]) were initially thought to interact selectively with mutant proteins in much the same way as the compounds discussed above. It was later discovered that the active species are not the agents as synthesized, but rather reactive breakdown products that form covalent adducts with a variety of nucleophilic groups via hetero-Michael addition reactions [<xref rid="B76-biomolecules-10-00303" ref-type="bibr">76</xref>]. By alkylating cellular thiol groups, the methylene quinuclidinone (MQ) decomposition product of APR-246 depletes cellular glutathione [<xref rid="B77-biomolecules-10-00303" ref-type="bibr">77</xref>,<xref rid="B78-biomolecules-10-00303" ref-type="bibr">78</xref>], inhibits thioredoxin and glutaredoxin systems [<xref rid="B79-biomolecules-10-00303" ref-type="bibr">79</xref>,<xref rid="B80-biomolecules-10-00303" ref-type="bibr">80</xref>], and inhibits ribonucleotide reductase [<xref rid="B80-biomolecules-10-00303" ref-type="bibr">80</xref>], leading to oxidative stress and cancer cell death through these p53-independent pathways [<xref rid="B81-biomolecules-10-00303" ref-type="bibr">81</xref>]. Nevertheless, MQ possesses p53-activating properties and APR-246 is under investigation in clinical trials enrolling cancer patients with mutant as well as unspecified p53 allele status. </p><p>The mechanisms by which covalent modifications activate p53 are becoming clearer. A recent study of APR-246 found that MQ alkylated up to five Cys residues in WT, R273H, and R175H DBD in a concentration-dependent manner, with C277 being the most reactive [<xref rid="B82-biomolecules-10-00303" ref-type="bibr">82</xref>]. Alkylation of C277 increased T<sub>m</sub> of all three variants and, together with modification of C124, this global stabilization effect may account for the rescue of R175H. C277 directly interacts with DNA and is in close proximity to R273, so it is conceivable that the C277 adduct could make additional contacts with DNA to compensate for the R273H alteration [<xref rid="B83-biomolecules-10-00303" ref-type="bibr">83</xref>]. The 2-sulfonylpyrimidine PK11007 [<xref rid="B84-biomolecules-10-00303" ref-type="bibr">84</xref>] and HO-3867 (an analog of the plant pigment curcumin) [<xref rid="B85-biomolecules-10-00303" ref-type="bibr">85</xref>] were also shown to be cysteine alkylators that preferentially attack C277 and C182 of DBD. PK11007 thermally stabilized Y220C DBD without compromising DNA binding affinity. PK11007, like PRIMA-1 [<xref rid="B86-biomolecules-10-00303" ref-type="bibr">86</xref>], inhibited aggregation of mutant p53. HO-3867 refolded mutant p53 in several cancer cell lines as judged by conformation-specific antibody staining. Although both compounds possess antiproliferative activity, they demonstrated varying degrees of selectivity toward killing cells with mutant p53 (compared to null and WT p53 cell lines), consistent with their action via both p53-dependent and independent routes [<xref rid="B84-biomolecules-10-00303" ref-type="bibr">84</xref>,<xref rid="B85-biomolecules-10-00303" ref-type="bibr">85</xref>,<xref rid="B87-biomolecules-10-00303" ref-type="bibr">87</xref>,<xref rid="B88-biomolecules-10-00303" ref-type="bibr">88</xref>]. </p></sec><sec id="sec8-biomolecules-10-00303"><title>8. Challenges and Outlook </title><p>By degrees, p53&#x02019;s reputation as being undruggable is being chipped away. The affinity of Y220C-specific molecules has increased ~100 fold since PK083 and further optimizations may be anticipated. Another need is to identify new druggable pockets in other stability-class mutants. The search for DNA-contact class reactivators progressed a step with SLMP53-1. The proposed mechanism and binding pocket await validation by biochemical and structural experiments, but the discovery of a p53&#x02013;DNA bridging molecule would represent a significant advancement. The clinical route for the above molecules is a classic one, taken by many drug development programs: improve the affinity and selectivity of the compounds for their targets. ZMC therapy is unique because, without a direct ZMC-p53 interaction, the pharmacological agent is not the ZMC but rather the zinc ion itself. The challenge is not to increase the strength of the ZMC-Zn<sup>2+</sup> interaction&#x02014;the optimal affinity range is already known and achievable [<xref rid="B52-biomolecules-10-00303" ref-type="bibr">52</xref>]&#x02014;but to minimize off-target effects and overcome the cellular zinc muffling response (which results in a resistance phenotype). The former problem may be addressed by &#x02018;dialing down&#x02019; the affinity for redox-active copper and/or iron ions, and the latter by a pulsatile dosing regimen that elevates intracellular zinc levels long enough to refold reservoirs of mutant p53 but not long enough to invoke a sustained transcriptional program that elevates zinc exporter and metallothionein levels. </p><p>In conclusion, as tremendous resources continue to be invested in drug discovery and design, it is important to recognize that only a small slice of the p53 mutational spectrum has been characterized. Missense mutations in over 190 of the 220 codons in DBD have been observed in human cancers [<xref rid="B9-biomolecules-10-00303" ref-type="bibr">9</xref>]. We suggest that measuring three basic properties of these variants&#x02014;<italic>K<sub>d</sub></italic><sup>Zn</sup>, <italic>K<sub>d</sub></italic><sup>DNA</sup>, and &#x00394;G<sub>fold</sub>&#x02014;will identify those that will respond best to class-specific molecules and help stratify patients for personalized medicine when these drugs eventually become available. Killing cancer cells by p53-directed therapy will likely entail a multi-pronged tactic that targets GOF, p53&#x02019;s downstream pathways, and p53 mutant reactivation. Rescuing the DNA binding and transcriptional activities of mutant p53 is at the center of this approach and it may be considered the tip of the spear. </p></sec></body><back><notes><title>Funding</title><p>This work was funded by a subaward from National Institutes of Health Grant R01 CA200800.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author declares no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-biomolecules-10-00303"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Stojanov</surname><given-names>P.</given-names></name><name><surname>Mermel</surname><given-names>C.H.</given-names></name><name><surname>Garraway</surname><given-names>L.A.</given-names></name><name><surname>Golub</surname><given-names>T.R.</given-names></name><name><surname>Meyerson</surname><given-names>M.</given-names></name><name><surname>Gabriel</surname><given-names>S.B.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name></person-group><article-title>Discovery and saturation analysis of cancer genes across 21 tumor types</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12912</pub-id><pub-id pub-id-type="pmid">24390350</pub-id></element-citation></ref><ref id="B2-biomolecules-10-00303"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname><given-names>L.A.</given-names></name><name><surname>Soussi</surname><given-names>T.</given-names></name><name><surname>Korkut</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Schultz</surname><given-names>A.</given-names></name><name><surname>Cardenas</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Babur</surname><given-names>O.</given-names></name><name><surname>Hsu</surname><given-names>T.-K.</given-names></name><name><surname>Lichtarge</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas</article-title><source>Cell Rep.</source><year>2019</year><volume>28</volume><fpage>1370</fpage><lpage>1384.e5</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.001</pub-id><pub-id pub-id-type="pmid">31365877</pub-id></element-citation></ref><ref id="B3-biomolecules-10-00303"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freed-Pastor</surname><given-names>W.A.</given-names></name><name><surname>Prives</surname><given-names>C.</given-names></name></person-group><article-title>Mutant p53: One name, many proteins</article-title><source>Genes Dev.</source><year>2012</year><volume>26</volume><fpage>1268</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1101/gad.190678.112</pub-id><pub-id pub-id-type="pmid">22713868</pub-id></element-citation></ref><ref id="B4-biomolecules-10-00303"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubrey</surname><given-names>B.J.</given-names></name><name><surname>Kelly</surname><given-names>G.L.</given-names></name><name><surname>Janic</surname><given-names>A.</given-names></name><name><surname>Herold</surname><given-names>M.J.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name></person-group><article-title>How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?</article-title><source>Cell Death Differ.</source><year>2018</year><volume>25</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.169</pub-id><pub-id pub-id-type="pmid">29149101</pub-id></element-citation></ref><ref id="B5-biomolecules-10-00303"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.P.</given-names></name><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group><article-title>Mutant p53 partners in crime</article-title><source>Cell Death Differ.</source><year>2018</year><volume>25</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.185</pub-id><pub-id pub-id-type="pmid">29099488</pub-id></element-citation></ref><ref id="B6-biomolecules-10-00303"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>A.</given-names></name><name><surname>Kirsch</surname><given-names>D.G.</given-names></name><name><surname>McLaughlin</surname><given-names>M.E.</given-names></name><name><surname>Tuveson</surname><given-names>D.A.</given-names></name><name><surname>Grimm</surname><given-names>J.</given-names></name><name><surname>Lintault</surname><given-names>L.</given-names></name><name><surname>Newman</surname><given-names>J.</given-names></name><name><surname>Reczek</surname><given-names>E.E.</given-names></name><name><surname>Weissleder</surname><given-names>R.</given-names></name><name><surname>Jacks</surname><given-names>T.</given-names></name></person-group><article-title>Restoration of p53 function leads to tumour regression in vivo</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nature05541</pub-id><pub-id pub-id-type="pmid">17251932</pub-id></element-citation></ref><ref id="B7-biomolecules-10-00303"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>C.P.</given-names></name><name><surname>Brown-Swigart</surname><given-names>L.</given-names></name><name><surname>Evan</surname><given-names>G.I.</given-names></name></person-group><article-title>Modeling the therapeutic efficacy of p53 restoration in tumors</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>1323</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.12.007</pub-id><pub-id pub-id-type="pmid">17182091</pub-id></element-citation></ref><ref id="B8-biomolecules-10-00303"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Zender</surname><given-names>L.</given-names></name><name><surname>Miething</surname><given-names>C.</given-names></name><name><surname>Dickins</surname><given-names>R.A.</given-names></name><name><surname>Hernando</surname><given-names>E.</given-names></name><name><surname>Krizhanovsky</surname><given-names>V.</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1038/nature05529</pub-id><pub-id pub-id-type="pmid">17251933</pub-id></element-citation></ref><ref id="B9-biomolecules-10-00303"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baugh</surname><given-names>E.H.</given-names></name><name><surname>Ke</surname><given-names>H.</given-names></name><name><surname>Levine</surname><given-names>A.J.</given-names></name><name><surname>Bonneau</surname><given-names>R.A.</given-names></name><name><surname>Chan</surname><given-names>C.S.</given-names></name></person-group><article-title>Why are there hotspot mutations in the TP53 gene in human cancers?</article-title><source>Cell Death Differ.</source><year>2018</year><volume>25</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.180</pub-id><pub-id pub-id-type="pmid">29099487</pub-id></element-citation></ref><ref id="B10-biomolecules-10-00303"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y.</given-names></name><name><surname>Gorina</surname><given-names>S.</given-names></name><name><surname>Jeffrey</surname><given-names>P.D.</given-names></name><name><surname>Pavletich</surname><given-names>N.P.</given-names></name></person-group><article-title>Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1126/science.8023157</pub-id><pub-id pub-id-type="pmid">8023157</pub-id></element-citation></ref><ref id="B11-biomolecules-10-00303"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rufini</surname><given-names>A.</given-names></name><name><surname>Tucci</surname><given-names>P.</given-names></name><name><surname>Celardo</surname><given-names>I.</given-names></name><name><surname>Melino</surname><given-names>G.</given-names></name></person-group><article-title>Senescence and aging: The critical roles of p53</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>5129</fpage><lpage>5143</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.640</pub-id><pub-id pub-id-type="pmid">23416979</pub-id></element-citation></ref><ref id="B12-biomolecules-10-00303"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabapathy</surname><given-names>K.</given-names></name><name><surname>Lane</surname><given-names>D.P.</given-names></name></person-group><article-title>Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2018</year><volume>15</volume><fpage>13</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.151</pub-id><pub-id pub-id-type="pmid">28948977</pub-id></element-citation></ref><ref id="B13-biomolecules-10-00303"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbandi</surname><given-names>A.</given-names></name><name><surname>Jackson</surname><given-names>J.G.</given-names></name></person-group><article-title>Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity</article-title><source>NPJ Precis. Oncol.</source><year>2019</year><volume>3</volume><pub-id pub-id-type="doi">10.1038/s41698-018-0074-x</pub-id><pub-id pub-id-type="pmid">30623031</pub-id></element-citation></ref><ref id="B14-biomolecules-10-00303"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrova</surname><given-names>E.M.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: A new promise in cancer therapy</article-title><source>Cell Death Differ.</source><year>2017</year><volume>24</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.145</pub-id><pub-id pub-id-type="pmid">27935583</pub-id></element-citation></ref><ref id="B15-biomolecules-10-00303"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Tahaney</surname><given-names>W.M.</given-names></name><name><surname>Mazumdar</surname><given-names>A.</given-names></name><name><surname>Savage</surname><given-names>M.I.</given-names></name><name><surname>Brown</surname><given-names>P.H.</given-names></name></person-group><article-title>Molecularly targeted therapies for p53-mutant cancers</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>4171</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2575-0</pub-id><pub-id pub-id-type="pmid">28643165</pub-id></element-citation></ref><ref id="B16-biomolecules-10-00303"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>N.</given-names></name><name><surname>Attardi</surname><given-names>L.D.</given-names></name></person-group><article-title>The Transactivation Domains of the p53 Protein</article-title><source>Cold Spring Harb Perspect Med.</source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.1101/cshperspect.a026047</pub-id></element-citation></ref><ref id="B17-biomolecules-10-00303"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>G.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>Peuget</surname><given-names>S.</given-names></name><name><surname>Selivanova</surname><given-names>G.</given-names></name></person-group><article-title>Inhibition of p53 inhibitors: Progress, challenges and perspectives</article-title><source>J. Mol. Cell Biol.</source><year>2019</year><volume>11</volume><fpage>586</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjz075</pub-id><pub-id pub-id-type="pmid">31310659</pub-id></element-citation></ref><ref id="B18-biomolecules-10-00303"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Rescuing the function of mutant p53</article-title><source>Nat. Rev. Cancer</source><year>2001</year><volume>1</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/35094077</pub-id><pub-id pub-id-type="pmid">11900253</pub-id></element-citation></ref><ref id="B19-biomolecules-10-00303"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Henckel</surname><given-names>J.</given-names></name><name><surname>DeDecker</surname><given-names>B.S.</given-names></name><name><surname>Johnson</surname><given-names>C.M.</given-names></name><name><surname>Nikolova</surname><given-names>P.V.</given-names></name><name><surname>Proctor</surname><given-names>M.R.</given-names></name><name><surname>Lane</surname><given-names>D.P.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Thermodynamic stability of wild-type and mutant p53 core domain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1997</year><volume>94</volume><fpage>14338</fpage><lpage>14342</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.26.14338</pub-id><pub-id pub-id-type="pmid">9405613</pub-id></element-citation></ref><ref id="B20-biomolecules-10-00303"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Henckel</surname><given-names>J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>1245</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203434</pub-id><pub-id pub-id-type="pmid">10713666</pub-id></element-citation></ref><ref id="B21-biomolecules-10-00303"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Structure-function-rescue: The diverse nature of common p53 cancer mutants</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2226</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210291</pub-id><pub-id pub-id-type="pmid">17401432</pub-id></element-citation></ref><ref id="B22-biomolecules-10-00303"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J.S.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name></person-group><article-title>Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain</article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>2396</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1021/bi026635n</pub-id><pub-id pub-id-type="pmid">12600206</pub-id></element-citation></ref><ref id="B23-biomolecules-10-00303"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Blanden</surname><given-names>A.R.</given-names></name><name><surname>Narayanan</surname><given-names>S.</given-names></name><name><surname>Jayakumar</surname><given-names>L.</given-names></name><name><surname>Lubin</surname><given-names>D.</given-names></name><name><surname>Augeri</surname><given-names>D.</given-names></name><name><surname>Kimball</surname><given-names>S.D.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name><name><surname>Carpizo</surname><given-names>D.R.</given-names></name></person-group><article-title>Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>8879</fpage><lpage>8892</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2432</pub-id><pub-id pub-id-type="pmid">25294809</pub-id></element-citation></ref><ref id="B24-biomolecules-10-00303"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>K.-B.</given-names></name><name><surname>DeDecker</surname><given-names>B.S.</given-names></name><name><surname>Freund</surname><given-names>S.M.</given-names></name><name><surname>Proctor</surname><given-names>M.R.</given-names></name><name><surname>Bycroft</surname><given-names>M.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Hot-spot mutants of p53 core domain evince characteristic local structural changes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>8438</fpage><lpage>8442</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.15.8438</pub-id><pub-id pub-id-type="pmid">10411893</pub-id></element-citation></ref><ref id="B25-biomolecules-10-00303"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J.S.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name></person-group><article-title>Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature</article-title><source>Protein Sci.</source><year>2006</year><volume>15</volume><fpage>2457</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1110/ps.062324206</pub-id><pub-id pub-id-type="pmid">17001034</pub-id></element-citation></ref><ref id="B26-biomolecules-10-00303"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J.S.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name></person-group><article-title>Zn<sup>2+</sup>-dependent misfolding of the p53 DNA binding domain</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>2630</fpage><lpage>2639</lpage><pub-id pub-id-type="doi">10.1021/bi062106y</pub-id><pub-id pub-id-type="pmid">17297920</pub-id></element-citation></ref><ref id="B27-biomolecules-10-00303"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J.S.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name></person-group><article-title>Kinetic partitioning during folding of the p53 DNA binding domain</article-title><source>J. Mol. Biol.</source><year>2005</year><volume>350</volume><fpage>906</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.05.060</pub-id><pub-id pub-id-type="pmid">15982667</pub-id></element-citation></ref><ref id="B28-biomolecules-10-00303"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschmidt</surname><given-names>L.</given-names></name><name><surname>Teng</surname><given-names>P.K.</given-names></name><name><surname>Riek</surname><given-names>R.</given-names></name><name><surname>Eisenberg</surname><given-names>D.</given-names></name></person-group><article-title>Identifying the amylome, proteins capable of forming amyloid-like fibrils</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>3487</fpage><lpage>3492</lpage><pub-id pub-id-type="doi">10.1073/pnas.0915166107</pub-id><pub-id pub-id-type="pmid">20133726</pub-id></element-citation></ref><ref id="B29-biomolecules-10-00303"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name><name><surname>Ranganathan</surname><given-names>S.</given-names></name><name><surname>Anoop</surname><given-names>A.</given-names></name><name><surname>Santosh Kuma</surname><given-names>P.</given-names></name><name><surname>Jha</surname><given-names>N.N.</given-names></name><name><surname>Padinhateeri</surname><given-names>R.</given-names></name><name><surname>Maji</surname><given-names>S.K.</given-names></name></person-group><article-title>Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in p53</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>5995</fpage><lpage>6010</lpage><pub-id pub-id-type="doi">10.1021/bi500825d</pub-id><pub-id pub-id-type="pmid">25181279</pub-id></element-citation></ref><ref id="B30-biomolecules-10-00303"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimaru</surname><given-names>D.</given-names></name><name><surname>Andrade</surname><given-names>L.R.</given-names></name><name><surname>Teixeira</surname><given-names>L.S.P.</given-names></name><name><surname>Quesado</surname><given-names>P.A.</given-names></name><name><surname>Maiolino</surname><given-names>L.M.</given-names></name><name><surname>Lopez</surname><given-names>P.M.</given-names></name><name><surname>Cordeiro</surname><given-names>Y.</given-names></name><name><surname>Costa</surname><given-names>L.T.</given-names></name><name><surname>Heckl</surname><given-names>W.M.</given-names></name><name><surname>Weissm&#x000fc;ller</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Fibrillar aggregates of the tumor suppressor p53 core domain</article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>9022</fpage><lpage>9027</lpage><pub-id pub-id-type="doi">10.1021/bi034218k</pub-id><pub-id pub-id-type="pmid">12885235</pub-id></element-citation></ref><ref id="B31-biomolecules-10-00303"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Boeckler</surname><given-names>F.M.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>13584</fpage><lpage>13589</lpage><pub-id pub-id-type="doi">10.1073/pnas.1211550109</pub-id><pub-id pub-id-type="pmid">22869713</pub-id></element-citation></ref><ref id="B32-biomolecules-10-00303"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Salot</surname><given-names>S.</given-names></name><name><surname>Sengupta</surname><given-names>S.</given-names></name><name><surname>Navalkar</surname><given-names>A.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name><name><surname>Jacob</surname><given-names>R.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Jha</surname><given-names>N.N.</given-names></name><name><surname>Sahay</surname><given-names>S.</given-names></name><etal/></person-group><article-title>p53 amyloid formation leading to its loss of function: Implications in cancer pathogenesis</article-title><source>Cell Death Differ.</source><year>2017</year><volume>24</volume><fpage>1784</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.105</pub-id><pub-id pub-id-type="pmid">28644435</pub-id></element-citation></ref><ref id="B33-biomolecules-10-00303"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bom</surname><given-names>A.P.D.A.</given-names></name><name><surname>Rangel</surname><given-names>L.P.</given-names></name><name><surname>Costa</surname><given-names>D.C.F.</given-names></name><name><surname>de Oliveira</surname><given-names>G.A.P.</given-names></name><name><surname>Sanches</surname><given-names>D.</given-names></name><name><surname>Braga</surname><given-names>C.A.</given-names></name><name><surname>Gava</surname><given-names>L.M.</given-names></name><name><surname>Ramos</surname><given-names>C.H.I.</given-names></name><name><surname>Cepeda</surname><given-names>A.O.T.</given-names></name><name><surname>Stumbo</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils IMPLICATIONS FOR CANCER</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>28152</fpage><lpage>28162</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.340638</pub-id><pub-id pub-id-type="pmid">22715097</pub-id></element-citation></ref><ref id="B34-biomolecules-10-00303"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smet</surname><given-names>F.D.</given-names></name><name><surname>Rubio</surname><given-names>M.S.</given-names></name><name><surname>Hompes</surname><given-names>D.</given-names></name><name><surname>Naus</surname><given-names>E.</given-names></name><name><surname>Baets</surname><given-names>G.D.</given-names></name><name><surname>Langenberg</surname><given-names>T.</given-names></name><name><surname>Hipp</surname><given-names>M.S.</given-names></name><name><surname>Houben</surname><given-names>B.</given-names></name><name><surname>Claes</surname><given-names>F.</given-names></name><name><surname>Charbonneau</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nuclear inclusion bodies of mutant and wild-type p53 in cancer: A hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation</article-title><source>J. Pathol.</source><year>2017</year><volume>242</volume><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/path.4872</pub-id><pub-id pub-id-type="pmid">28035683</pub-id></element-citation></ref><ref id="B35-biomolecules-10-00303"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckler</surname><given-names>F.M.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Jaggi</surname><given-names>G.</given-names></name><name><surname>Rutherford</surname><given-names>T.J.</given-names></name><name><surname>Veprintsev</surname><given-names>D.B.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Targeted rescue of a destabilized mutant of p53 by an in silico screened drug</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>10360</fpage><lpage>10365</lpage><pub-id pub-id-type="doi">10.1073/pnas.0805326105</pub-id><pub-id pub-id-type="pmid">18650397</pub-id></element-citation></ref><ref id="B36-biomolecules-10-00303"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Chuckowree</surname><given-names>I.S.</given-names></name><name><surname>Amin</surname><given-names>J.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Small molecule induced reactivation of mutant p53 in cancer cells</article-title><source>Nucleic. Acids Res.</source><year>2013</year><volume>41</volume><fpage>6034</fpage><lpage>6044</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt305</pub-id><pub-id pub-id-type="pmid">23630318</pub-id></element-citation></ref><ref id="B37-biomolecules-10-00303"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Zimmermann</surname><given-names>M.O.</given-names></name><name><surname>Lange</surname><given-names>A.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Boeckler</surname><given-names>F.M.</given-names></name></person-group><article-title>Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>1363</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1021/jm3012068</pub-id><pub-id pub-id-type="pmid">23145854</pub-id></element-citation></ref><ref id="B38-biomolecules-10-00303"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Jones</surname><given-names>R.N.</given-names></name><name><surname>Baud</surname><given-names>M.G.J.</given-names></name><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Boeckler</surname><given-names>F.M.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name></person-group><article-title>Harnessing Fluorine&#x02013;Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs</article-title><source>ACS Chem. Biol.</source><year>2016</year><volume>11</volume><fpage>2265</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b00315</pub-id><pub-id pub-id-type="pmid">27267810</pub-id></element-citation></ref><ref id="B39-biomolecules-10-00303"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zimmermann</surname><given-names>M.O.</given-names></name><name><surname>Rutherford</surname><given-names>T.J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Boeckler</surname><given-names>F.M.</given-names></name></person-group><article-title>Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>6810</fpage><lpage>6818</lpage><pub-id pub-id-type="doi">10.1021/ja301056a</pub-id><pub-id pub-id-type="pmid">22439615</pub-id></element-citation></ref><ref id="B40-biomolecules-10-00303"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Jones</surname><given-names>R.N.</given-names></name><name><surname>Tareque</surname><given-names>R.K.</given-names></name><name><surname>Springett</surname><given-names>B.</given-names></name><name><surname>Dingler</surname><given-names>F.A.</given-names></name><name><surname>Verduci</surname><given-names>L.</given-names></name><name><surname>Patel</surname><given-names>K.J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name></person-group><article-title>A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C</article-title><source>Future Med.Chem.</source><year>2019</year><volume>11</volume><fpage>2491</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.4155/fmc-2019-0181</pub-id><pub-id pub-id-type="pmid">31633398</pub-id></element-citation></ref><ref id="B41-biomolecules-10-00303"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baud</surname><given-names>M.G.J.</given-names></name><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Verduci</surname><given-names>L.</given-names></name><name><surname>Dingler</surname><given-names>F.A.</given-names></name><name><surname>Patel</surname><given-names>K.J.</given-names></name><name><surname>Horil Roy</surname><given-names>D.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>152</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.04.035</pub-id><pub-id pub-id-type="pmid">29702446</pub-id></element-citation></ref><ref id="B42-biomolecules-10-00303"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wassman</surname><given-names>C.D.</given-names></name><name><surname>Baronio</surname><given-names>R.</given-names></name><name><surname>Demir</surname><given-names>O.</given-names></name><name><surname>Wallentine</surname><given-names>B.D.</given-names></name><name><surname>Chen</surname><given-names>C.K.</given-names></name><name><surname>Hall</surname><given-names>L.V.</given-names></name><name><surname>Salehi</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>D.W.</given-names></name><name><surname>Chung</surname><given-names>B.P.</given-names></name><name><surname>Hatfield</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>1407</fpage><pub-id pub-id-type="doi">10.1038/ncomms2361</pub-id><pub-id pub-id-type="pmid">23360998</pub-id></element-citation></ref><ref id="B43-biomolecules-10-00303"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromley</surname><given-names>D.</given-names></name><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><name><surname>Daggett</surname><given-names>V.</given-names></name></person-group><article-title>An in silico algorithm for identifying stabilizing pockets in proteins: Test case, the Y220C mutant of the p53 tumor suppressor protein</article-title><source>Protein Eng. Des. Sel.</source><year>2016</year><volume>29</volume><fpage>377</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1093/protein/gzw035</pub-id><pub-id pub-id-type="pmid">27503952</pub-id></element-citation></ref><ref id="B44-biomolecules-10-00303"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Wilcken</surname><given-names>R.</given-names></name><name><surname>Baud</surname><given-names>M.G.J.</given-names></name><name><surname>Harbrecht</surname><given-names>H.</given-names></name><name><surname>Exner</surname><given-names>T.E.</given-names></name><name><surname>Boeckler</surname><given-names>F.M.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53</article-title><source>Structure</source><year>2015</year><volume>23</volume><fpage>2246</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.10.016</pub-id><pub-id pub-id-type="pmid">26636255</pub-id></element-citation></ref><ref id="B45-biomolecules-10-00303"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>M.R.</given-names></name><name><surname>Siau</surname><given-names>J.W.</given-names></name><name><surname>Kannan</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>M.N.</given-names></name><name><surname>Ouaray</surname><given-names>Z.</given-names></name><name><surname>Kwoh</surname><given-names>C.K.</given-names></name><name><surname>Lane</surname><given-names>D.P.</given-names></name><name><surname>Ghadessy</surname><given-names>F.</given-names></name><name><surname>Verma</surname><given-names>C.S.</given-names></name></person-group><article-title>Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket</article-title><source>Nucleic. Acids Res.</source><year>2019</year><volume>47</volume><fpage>1637</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1314</pub-id><pub-id pub-id-type="pmid">30649466</pub-id></element-citation></ref><ref id="B46-biomolecules-10-00303"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tal</surname><given-names>P.</given-names></name><name><surname>Eizenberger</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>E.</given-names></name><name><surname>Goldfinger</surname><given-names>N.</given-names></name><name><surname>Pietrokovski</surname><given-names>S.</given-names></name><name><surname>Oren</surname><given-names>M.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name></person-group><article-title>Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>11817</fpage><lpage>11837</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7857</pub-id><pub-id pub-id-type="pmid">26943582</pub-id></element-citation></ref><ref id="B47-biomolecules-10-00303"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>S.N.</given-names></name></person-group><article-title>The missing zinc: p53 misfolding and cancer</article-title><source>Metallomics</source><year>2010</year><volume>2</volume><fpage>442</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1039/c003915b</pub-id><pub-id pub-id-type="pmid">21072344</pub-id></element-citation></ref><ref id="B48-biomolecules-10-00303"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Vazquez</surname><given-names>A.</given-names></name><name><surname>Levine</surname><given-names>A.J.</given-names></name><name><surname>Carpizo</surname><given-names>D.R.</given-names></name></person-group><article-title>Allele-specific p53 mutant reactivation</article-title><source>Cancer Cell</source><year>2012</year><volume>21</volume><fpage>614</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.03.042</pub-id><pub-id pub-id-type="pmid">22624712</pub-id></element-citation></ref><ref id="B49-biomolecules-10-00303"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanden</surname><given-names>A.R.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name><name><surname>Levine</surname><given-names>A.J.</given-names></name><name><surname>Carpizo</surname><given-names>D.R.</given-names></name></person-group><article-title>Reactivating mutant p53 using small molecules as zinc metallochaperones: Awakening a sleeping giant in cancer</article-title><source>Drug Discov. Today</source><year>2015</year><volume>20</volume><fpage>1391</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2015.07.006</pub-id><pub-id pub-id-type="pmid">26205328</pub-id></element-citation></ref><ref id="B50-biomolecules-10-00303"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Withers</surname><given-names>T.</given-names></name><name><surname>Gilleran</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>M.</given-names></name><name><surname>Foo</surname><given-names>T.K.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Moore</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Kimball</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation</article-title><source>NPJ Breast Cancer</source><year>2019</year><volume>5</volume><pub-id pub-id-type="doi">10.1038/s41523-019-0110-1</pub-id></element-citation></ref><ref id="B51-biomolecules-10-00303"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Kogan</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Tsang</surname><given-names>A.T.</given-names></name><name><surname>Withers</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Gilleran</surname><given-names>J.</given-names></name><name><surname>Buckley</surname><given-names>B.</given-names></name><name><surname>Moore</surname><given-names>D.</given-names></name><name><surname>Bertino</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics</article-title><source>Clin. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>4505</fpage><lpage>4517</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0822</pub-id><pub-id pub-id-type="pmid">29914895</pub-id></element-citation></ref><ref id="B52-biomolecules-10-00303"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Blanden</surname><given-names>A.</given-names></name><name><surname>Tsang</surname><given-names>A.T.</given-names></name><name><surname>Zaman</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gilleran</surname><given-names>J.</given-names></name><name><surname>Bencivenga</surname><given-names>A.F.</given-names></name><name><surname>Kimball</surname><given-names>S.D.</given-names></name><name><surname>Loh</surname><given-names>S.N.</given-names></name><name><surname>Carpizo</surname><given-names>D.R.</given-names></name></person-group><article-title>Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53</article-title><source>Mol. Pharmacol.</source><year>2017</year><volume>91</volume><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1124/mol.116.107409</pub-id><pub-id pub-id-type="pmid">28320780</pub-id></element-citation></ref><ref id="B53-biomolecules-10-00303"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salim</surname><given-names>K.Y.</given-names></name><name><surname>Maleki Vareki</surname><given-names>S.</given-names></name><name><surname>Danter</surname><given-names>W.R.</given-names></name><name><surname>Koropatnick</surname><given-names>J.</given-names></name></person-group><article-title>COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>41363</fpage><lpage>41379</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9133</pub-id><pub-id pub-id-type="pmid">27150056</pub-id></element-citation></ref><ref id="B54-biomolecules-10-00303"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindemann</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>A.A.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Silver</surname><given-names>N.L.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Rao</surname><given-names>X.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Maduka</surname><given-names>N.K.</given-names></name><etal/></person-group><article-title>COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms</article-title><source>Clin. Cancer Res.</source><year>2019</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0096</pub-id><pub-id pub-id-type="pmid">31308060</pub-id></element-citation></ref><ref id="B55-biomolecules-10-00303"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakin</surname><given-names>N.D.</given-names></name><name><surname>Jackson</surname><given-names>S.P.</given-names></name></person-group><article-title>Regulation of p53 in response to DNA damage</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>7644</fpage><lpage>7655</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203015</pub-id><pub-id pub-id-type="pmid">10618704</pub-id></element-citation></ref><ref id="B56-biomolecules-10-00303"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Reznik</surname><given-names>E.</given-names></name><name><surname>Stokes</surname><given-names>M.E.</given-names></name><name><surname>Krishnamoorthy</surname><given-names>L.</given-names></name><name><surname>Bos</surname><given-names>P.H.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Quartararo</surname><given-names>C.E.</given-names></name><name><surname>Pagano</surname><given-names>N.C.</given-names></name><name><surname>Carpizo</surname><given-names>D.R.</given-names></name><name><surname>deCarvalho</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells</article-title><source>Cell Chem. Biol.</source><year>2018</year><volume>25</volume><fpage>585</fpage><lpage>594.e7</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.02.010</pub-id><pub-id pub-id-type="pmid">29576531</pub-id></element-citation></ref><ref id="B57-biomolecules-10-00303"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Bencivenga</surname><given-names>A.F.</given-names></name><name><surname>Blanden</surname><given-names>A.R.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Withers</surname><given-names>T.</given-names></name><name><surname>Na</surname><given-names>B.</given-names></name><name><surname>Blayney</surname><given-names>A.J.</given-names></name><name><surname>Gilleran</surname><given-names>J.</given-names></name><name><surname>Boothman</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Combinatorial therapy of Zinc metallochaperones with mutant p53 reactivation and diminished copper binding</article-title><source>Mol. Cancer Ther.</source><year>2019</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-1080</pub-id></element-citation></ref><ref id="B58-biomolecules-10-00303"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J.J.</given-names></name><name><surname>Orvain</surname><given-names>C.</given-names></name><name><surname>Jozi</surname><given-names>S.</given-names></name><name><surname>Clarke</surname><given-names>R.M.</given-names></name><name><surname>Smith</surname><given-names>J.R.</given-names></name><name><surname>Blanchet</surname><given-names>A.</given-names></name><name><surname>Gaiddon</surname><given-names>C.</given-names></name><name><surname>Warren</surname><given-names>J.J.</given-names></name><name><surname>Storr</surname><given-names>T.</given-names></name></person-group><article-title>Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer</article-title><source>Chemistry A</source><year>2018</year><volume>24</volume><fpage>17734</fpage><lpage>17742</lpage><pub-id pub-id-type="doi">10.1002/chem.201802677</pub-id></element-citation></ref><ref id="B59-biomolecules-10-00303"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Ang</surname><given-names>H.C.</given-names></name><name><surname>Veprintsev</surname><given-names>D.B.</given-names></name><name><surname>Blair</surname><given-names>C.M.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>16030</fpage><lpage>16037</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500179200</pub-id><pub-id pub-id-type="pmid">15703170</pub-id></element-citation></ref><ref id="B60-biomolecules-10-00303"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baroni</surname><given-names>T.E.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Qian</surname><given-names>H.</given-names></name><name><surname>Dearth</surname><given-names>L.R.</given-names></name><name><surname>Truong</surname><given-names>L.N.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Denes</surname><given-names>A.E.</given-names></name><name><surname>Chen</surname><given-names>S.W.</given-names></name><name><surname>Brachmann</surname><given-names>R.K.</given-names></name></person-group><article-title>A global suppressor motif for p53 cancer mutants</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>4930</fpage><lpage>4935</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401162101</pub-id><pub-id pub-id-type="pmid">15037740</pub-id></element-citation></ref><ref id="B61-biomolecules-10-00303"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasquinha</surname><given-names>J.A.</given-names></name><name><surname>Bej</surname><given-names>A.</given-names></name><name><surname>Dutta</surname><given-names>S.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group><article-title>Intrinsic Differences in Backbone Dynamics between Wild Type and DNA-Contact Mutants of the p53 DNA Binding Domain Revealed by Nuclear Magnetic Resonance Spectroscopy</article-title><source>Biochemistry</source><year>2017</year><volume>56</volume><fpage>4962</fpage><lpage>4971</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.7b00514</pub-id><pub-id pub-id-type="pmid">28836764</pub-id></element-citation></ref><ref id="B62-biomolecules-10-00303"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>A.S.</given-names></name><name><surname>Ramos</surname><given-names>H.</given-names></name><name><surname>Gomes</surname><given-names>S.</given-names></name><name><surname>Loureiro</surname><given-names>J.B.</given-names></name><name><surname>Soares</surname><given-names>J.</given-names></name><name><surname>Barcherini</surname><given-names>V.</given-names></name><name><surname>Monti</surname><given-names>P.</given-names></name><name><surname>Fronza</surname><given-names>G.</given-names></name><name><surname>Oliveira</surname><given-names>C.</given-names></name><name><surname>Domingues</surname><given-names>L.</given-names></name><etal/></person-group><article-title>SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations</article-title><source>Biochim. Biophys. Acta</source><year>2020</year><volume>1864</volume><fpage>129440</fpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2019.129440</pub-id><pub-id pub-id-type="pmid">31536751</pub-id></element-citation></ref><ref id="B63-biomolecules-10-00303"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>J.</given-names></name><name><surname>Raimundo</surname><given-names>L.</given-names></name><name><surname>Pereira</surname><given-names>N.A.L.</given-names></name><name><surname>Monteiro</surname><given-names>&#x000c2;.</given-names></name><name><surname>Gomes</surname><given-names>S.</given-names></name><name><surname>Bessa</surname><given-names>C.</given-names></name><name><surname>Pereira</surname><given-names>C.</given-names></name><name><surname>Queiroz</surname><given-names>G.</given-names></name><name><surname>Bisio</surname><given-names>A.</given-names></name><name><surname>Fernandes</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>4326</fpage><lpage>4343</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6775</pub-id><pub-id pub-id-type="pmid">26735173</pub-id></element-citation></ref><ref id="B64-biomolecules-10-00303"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>J.L.</given-names></name><name><surname>Cino</surname><given-names>E.A.</given-names></name><name><surname>Soares</surname><given-names>I.N.</given-names></name><name><surname>Ferreira</surname><given-names>V.F.</given-names></name><name><surname>de Oliveira</surname><given-names>A.P.G.</given-names></name></person-group><article-title>Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer</article-title><source>Acc. Chem. Res.</source><year>2018</year><volume>51</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.7b00473</pub-id><pub-id pub-id-type="pmid">29260852</pub-id></element-citation></ref><ref id="B65-biomolecules-10-00303"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navalkar</surname><given-names>A.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Datta</surname><given-names>D.</given-names></name><name><surname>Maji</surname><given-names>S.K.</given-names></name></person-group><article-title>Prion-like p53 Amyloids in Cancer</article-title><source>Biochemistry</source><year>2019</year><pub-id pub-id-type="doi">10.1021/acs.biochem.9b00796</pub-id></element-citation></ref><ref id="B66-biomolecules-10-00303"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawaya</surname><given-names>M.R.</given-names></name><name><surname>Sambashivan</surname><given-names>S.</given-names></name><name><surname>Nelson</surname><given-names>R.</given-names></name><name><surname>Ivanova</surname><given-names>M.I.</given-names></name><name><surname>Sievers</surname><given-names>S.A.</given-names></name><name><surname>Apostol</surname><given-names>M.I.</given-names></name><name><surname>Thompson</surname><given-names>M.J.</given-names></name><name><surname>Balbirnie</surname><given-names>M.</given-names></name><name><surname>Wiltzius</surname><given-names>J.J.W.</given-names></name><name><surname>McFarlane</surname><given-names>H.T.</given-names></name><etal/></person-group><article-title>Atomic structures of amyloid cross-beta spines reveal varied steric zippers</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nature05695</pub-id><pub-id pub-id-type="pmid">17468747</pub-id></element-citation></ref><ref id="B67-biomolecules-10-00303"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soragni</surname><given-names>A.</given-names></name><name><surname>Janzen</surname><given-names>D.M.</given-names></name><name><surname>Johnson</surname><given-names>L.M.</given-names></name><name><surname>Lindgren</surname><given-names>A.G.</given-names></name><name><surname>Thai-Quynh Nguyen</surname><given-names>A.</given-names></name><name><surname>Tiourin</surname><given-names>E.</given-names></name><name><surname>Soriaga</surname><given-names>A.B.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Faull</surname><given-names>K.F.</given-names></name><etal/></person-group><article-title>A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas</article-title><source>Cancer Cell</source><year>2016</year><volume>29</volume><fpage>90</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.12.002</pub-id><pub-id pub-id-type="pmid">26748848</pub-id></element-citation></ref><ref id="B68-biomolecules-10-00303"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Butler</surname><given-names>W.</given-names></name><name><surname>Jin</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC</article-title><source>Prostate Cancer Prostatic Dis.</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41391-019-0172-z</pub-id></element-citation></ref><ref id="B69-biomolecules-10-00303"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimaru</surname><given-names>D.</given-names></name><name><surname>Ano Bom</surname><given-names>A.P.</given-names></name><name><surname>Lima</surname><given-names>L.M.</given-names></name><name><surname>Quesado</surname><given-names>P.A.</given-names></name><name><surname>Oyama</surname><given-names>M.F.</given-names></name><name><surname>de Moura Gallo</surname><given-names>C.V.</given-names></name><name><surname>Cordeiro</surname><given-names>Y.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name></person-group><article-title>Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>6126</fpage><lpage>6135</lpage><pub-id pub-id-type="doi">10.1021/bi9003028</pub-id><pub-id pub-id-type="pmid">19505151</pub-id></element-citation></ref><ref id="B70-biomolecules-10-00303"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>J.L.</given-names></name><name><surname>Vieira</surname><given-names>T.C.R.G.</given-names></name><name><surname>Gomes</surname><given-names>M.P.B.</given-names></name><name><surname>Bom</surname><given-names>A.P.A.</given-names></name><name><surname>Lima</surname><given-names>L.M.T.R.</given-names></name><name><surname>Freitas</surname><given-names>M.S.</given-names></name><name><surname>Ishimaru</surname><given-names>D.</given-names></name><name><surname>Cordeiro</surname><given-names>Y.</given-names></name><name><surname>Foguel</surname><given-names>D.</given-names></name></person-group><article-title>Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins</article-title><source>Acc. Chem. Res.</source><year>2010</year><volume>43</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1021/ar900179t</pub-id><pub-id pub-id-type="pmid">19817406</pub-id></element-citation></ref><ref id="B71-biomolecules-10-00303"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovachev</surname><given-names>P.S.</given-names></name><name><surname>Banerjee</surname><given-names>D.</given-names></name><name><surname>Rangel</surname><given-names>L.P.</given-names></name><name><surname>Eriksson</surname><given-names>J.</given-names></name><name><surname>Pedrote</surname><given-names>M.M.</given-names></name><name><surname>Martins-Dinis</surname><given-names>M.M.D.C.</given-names></name><name><surname>Edwards</surname><given-names>K.</given-names></name><name><surname>Cordeiro</surname><given-names>Y.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name><name><surname>Sanyal</surname><given-names>S.</given-names></name></person-group><article-title>Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>9345</fpage><lpage>9357</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.762096</pub-id><pub-id pub-id-type="pmid">28420731</pub-id></element-citation></ref><ref id="B72-biomolecules-10-00303"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Keshamouni</surname><given-names>V.G.</given-names></name><name><surname>Kanapathipillai</surname><given-names>M.</given-names></name></person-group><article-title>Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro</article-title><source>Biochem. Biophy. Res. Commun.</source><year>2017</year><volume>489</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.05.111</pub-id><pub-id pub-id-type="pmid">28536076</pub-id></element-citation></ref><ref id="B73-biomolecules-10-00303"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Costa</surname><given-names>D.C.F.</given-names></name><name><surname>Campos</surname><given-names>N.P.C.</given-names></name><name><surname>Santos</surname><given-names>R.A.</given-names></name><name><surname>Guedes-da-Silva</surname><given-names>F.H.</given-names></name><name><surname>Martins-Dinis</surname><given-names>M.M.D.C.</given-names></name><name><surname>Zanphorlin</surname><given-names>L.</given-names></name><name><surname>Ramos</surname><given-names>C.</given-names></name><name><surname>Rangel</surname><given-names>L.P.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name></person-group><article-title>Resveratrol prevents p53 aggregation in vitro and in breast cancer cells</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>29112</fpage><lpage>29122</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25631</pub-id><pub-id pub-id-type="pmid">30018739</pub-id></element-citation></ref><ref id="B74-biomolecules-10-00303"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>B.A.</given-names></name><name><surname>Coffey</surname><given-names>H.A.</given-names></name><name><surname>Morin</surname><given-names>M.J.</given-names></name><name><surname>Rasitnejad</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacological rescue of mutant p53 conformation and function</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>2507</fpage><lpage>2510</lpage><pub-id pub-id-type="doi">10.1126/science.286.5449.2507</pub-id><pub-id pub-id-type="pmid">10617466</pub-id></element-citation></ref><ref id="B75-biomolecules-10-00303"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bykov</surname><given-names>V.J.</given-names></name><name><surname>Issaeva</surname><given-names>N.</given-names></name><name><surname>Shilov</surname><given-names>A.</given-names></name><name><surname>Hultcrantz</surname><given-names>M.</given-names></name><name><surname>Pugacheva</surname><given-names>E.</given-names></name><name><surname>Chumakov</surname><given-names>P.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name><name><surname>Selivanova</surname><given-names>G.</given-names></name></person-group><article-title>Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound</article-title><source>Nat. Med.</source><year>2002</year><volume>8</volume><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/nm0302-282</pub-id><pub-id pub-id-type="pmid">11875500</pub-id></element-citation></ref><ref id="B76-biomolecules-10-00303"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>J.M.</given-names></name><name><surname>Gorzov</surname><given-names>P.</given-names></name><name><surname>Veprintsev</surname><given-names>D.B.</given-names></name><name><surname>Soderqvist</surname><given-names>M.</given-names></name><name><surname>Segerback</surname><given-names>D.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><name><surname>Hainaut</surname><given-names>P.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name><name><surname>Bykov</surname><given-names>V.J.</given-names></name></person-group><article-title>PRIMA-1 reactivates mutant p53 by covalent binding to the core domain</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>376</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.03.003</pub-id><pub-id pub-id-type="pmid">19411067</pub-id></element-citation></ref><ref id="B77-biomolecules-10-00303"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tessoulin</surname><given-names>B.</given-names></name><name><surname>Descamps</surname><given-names>G.</given-names></name><name><surname>Moreau</surname><given-names>P.</given-names></name><name><surname>Ma&#x000ef;ga</surname><given-names>S.</given-names></name><name><surname>Lod&#x000e9;</surname><given-names>L.</given-names></name><name><surname>Godon</surname><given-names>C.</given-names></name><name><surname>Marionneau-Lambot</surname><given-names>S.</given-names></name><name><surname>Oullier</surname><given-names>T.</given-names></name><name><surname>Le Gouill</surname><given-names>S.</given-names></name><name><surname>Amiot</surname><given-names>M.</given-names></name><etal/></person-group><article-title>PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>1626</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-01-548800</pub-id><pub-id pub-id-type="pmid">25006124</pub-id></element-citation></ref><ref id="B78-biomolecules-10-00303"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D.S.</given-names></name><name><surname>Duong</surname><given-names>C.P.</given-names></name><name><surname>Haupt</surname><given-names>S.</given-names></name><name><surname>Montgomery</surname><given-names>K.G.</given-names></name><name><surname>House</surname><given-names>C.M.</given-names></name><name><surname>Azar</surname><given-names>W.J.</given-names></name><name><surname>Pearson</surname><given-names>H.B.</given-names></name><name><surname>Fisher</surname><given-names>O.M.</given-names></name><name><surname>Read</surname><given-names>M.</given-names></name><name><surname>Guerra</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Inhibiting the system x C-/glutathione axis selectively targets cancers with mutant-p53 accumulation</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.1038/ncomms14844</pub-id></element-citation></ref><ref id="B79-biomolecules-10-00303"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>M.Q.</given-names></name><name><surname>Conserva</surname><given-names>F.</given-names></name><name><surname>Hosny</surname><given-names>G.</given-names></name><name><surname>Selivanova</surname><given-names>G.</given-names></name><name><surname>Bykov</surname><given-names>V.J.</given-names></name><name><surname>Arner</surname><given-names>E.S.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name></person-group><article-title>APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase</article-title><source>Cell Death Dis.</source><year>2013</year><volume>4</volume><fpage>e881</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.417</pub-id><pub-id pub-id-type="pmid">24157875</pub-id></element-citation></ref><ref id="B80-biomolecules-10-00303"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffo</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Bykov</surname><given-names>V.J.N.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Coppo</surname><given-names>L.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name><name><surname>Holmgren</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>12671</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-31048-7</pub-id><pub-id pub-id-type="pmid">30140002</pub-id></element-citation></ref><ref id="B81-biomolecules-10-00303"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name><name><surname>Bykov</surname><given-names>V.J.N.</given-names></name></person-group><article-title>Role of Thiol Reactivity for Targeting Mutant p53</article-title><source>Cell Chem. Biol.</source><year>2018</year><volume>25</volume><fpage>1219</fpage><lpage>1230.e3</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.06.013</pub-id><pub-id pub-id-type="pmid">30057300</pub-id></element-citation></ref><ref id="B82-biomolecules-10-00303"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Bykov</surname><given-names>V.J.N.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name><name><surname>Zawacka-Pankau</surname><given-names>J.</given-names></name></person-group><article-title>APR-246 reactivates mutant p53 by targeting cysteines 124 and 277</article-title><source>Cell Death Dis.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.1038/s41419-018-0463-7</pub-id><pub-id pub-id-type="pmid">29670092</pub-id></element-citation></ref><ref id="B83-biomolecules-10-00303"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omar</surname><given-names>S.I.</given-names></name><name><surname>Tuszynski</surname><given-names>J.</given-names></name></person-group><article-title>The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>37137</fpage><lpage>37156</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26440</pub-id><pub-id pub-id-type="pmid">30647850</pub-id></element-citation></ref><ref id="B84-biomolecules-10-00303"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E5271</fpage><lpage>E5280</lpage><pub-id pub-id-type="doi">10.1073/pnas.1610421113</pub-id><pub-id pub-id-type="pmid">27551077</pub-id></element-citation></ref><ref id="B85-biomolecules-10-00303"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>E.</given-names></name><name><surname>Parker</surname><given-names>T.M.</given-names></name><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Dhiman</surname><given-names>A.</given-names></name><name><surname>Pelham</surname><given-names>C.J.</given-names></name><name><surname>Nagane</surname><given-names>M.</given-names></name><name><surname>Kuppusamy</surname><given-names>M.L.</given-names></name><name><surname>Holmes</surname><given-names>M.</given-names></name><name><surname>Holmes</surname><given-names>T.R.</given-names></name><name><surname>Shaik</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>4262</fpage><lpage>4276</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.000950</pub-id><pub-id pub-id-type="pmid">29382728</pub-id></element-citation></ref><ref id="B86-biomolecules-10-00303"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangel</surname><given-names>L.P.</given-names></name><name><surname>Ferretti</surname><given-names>G.D.S.</given-names></name><name><surname>Costa</surname><given-names>C.L.</given-names></name><name><surname>Andrade</surname><given-names>S.M.M.V.</given-names></name><name><surname>Carvalho</surname><given-names>R.S.</given-names></name><name><surname>Costa</surname><given-names>D.C.F.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name></person-group><article-title>p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells</article-title><source>J. Biol. Chem.</source><year>2019</year><pub-id pub-id-type="doi">10.1074/jbc.RA118.004671</pub-id></element-citation></ref><ref id="B87-biomolecules-10-00303"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Synnott</surname><given-names>N.C.</given-names></name><name><surname>Bauer</surname><given-names>M.R.</given-names></name><name><surname>Madden</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>A.</given-names></name><name><surname>Klinger</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>N.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>D.</given-names></name><name><surname>Gallagher</surname><given-names>W.M.</given-names></name><name><surname>Crown</surname><given-names>J.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007</article-title><source>Cancer Lett.</source><year>2018</year><volume>414</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.09.053</pub-id><pub-id pub-id-type="pmid">29069577</pub-id></element-citation></ref><ref id="B88-biomolecules-10-00303"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.-C.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Khoshaba</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>F.-G.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>F.-L.</given-names></name><name><surname>Liao</surname><given-names>D.-F.</given-names></name><name><surname>Cao</surname><given-names>D.</given-names></name></person-group><article-title>Curcumin Nicotinate Selectively Induces Cancer Cell Apoptosis and Cycle Arrest through a P53-Mediated Mechanism</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>4179</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24224179</pub-id><pub-id pub-id-type="pmid">31752145</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="biomolecules-10-00303-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Locations of the top 10 most common somatic mutation sites in p53. The X-ray structure of wild-type (WT) DNA-binding domain (DBD) complexed to DNA is shown (PDB 1TSR). Mutational classes are colored as follows: DNA contact (purple), zinc binding (green), stability (yellow), mixed DNA-contact/stability (pink), and mixed zinc-binding/stability (orange). The zinc ion is the black sphere.</p></caption><graphic xlink:href="biomolecules-10-00303-g001"/></fig><fig id="biomolecules-10-00303-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cavity-binding compounds that target the stability class Y220C p53 mutant.</p></caption><graphic xlink:href="biomolecules-10-00303-g002"/></fig><fig id="biomolecules-10-00303-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Metallochaperones that target the zinc-binding and stability class mutants of p53.</p></caption><graphic xlink:href="biomolecules-10-00303-g003"/></fig><fig id="biomolecules-10-00303-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>SLMP53-1 compound that targets DNA-binding class mutants of p53.</p></caption><graphic xlink:href="biomolecules-10-00303-g004"/></fig><table-wrap id="biomolecules-10-00303-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">biomolecules-10-00303-t001_Table 1</object-id><label>Table 1</label><caption><p>Top10 most common somatic p53 mutation sites in IARC Database R20. If multiple mutations at a single site are among the top 50 most common, they are listed in order of decreasing occurrence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rank</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutants</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DNA Contact</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Zinc Binding</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stability</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">R248</td><td align="center" valign="top" rowspan="1" colspan="1">Gln, Trp</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>,<xref rid="B22-biomolecules-10-00303" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">R273</td><td align="center" valign="top" rowspan="1" colspan="1">His, Cys</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">R175</td><td align="center" valign="top" rowspan="1" colspan="1">His</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B23-biomolecules-10-00303" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">G245</td><td align="center" valign="top" rowspan="1" colspan="1">Ser, Asp, Cys, Val</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>,<xref rid="B23-biomolecules-10-00303" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">R249</td><td align="center" valign="top" rowspan="1" colspan="1">Ser</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>,<xref rid="B24-biomolecules-10-00303" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Y220</td><td align="center" valign="top" rowspan="1" colspan="1">Cys</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">C176</td><td align="center" valign="top" rowspan="1" colspan="1">Phe, Tyr</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B23-biomolecules-10-00303" ref-type="bibr">23</xref>]<sup>,1</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">H179</td><td align="center" valign="top" rowspan="1" colspan="1">Arg, Tyr</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
<sup>1</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">V157</td><td align="center" valign="top" rowspan="1" colspan="1">Phe</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">M237</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ile</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-biomolecules-10-00303" ref-type="bibr">20</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Zinc-coordinating residue.</p></fn></table-wrap-foot></table-wrap></floats-group></article>